



HHS PUBLIC ACCESS

Author manuscript

Cell Prolif. Author manuscript; available in PMC 2019 February 12.

Published in final edited form as:

Cell Prolif. 2011 April ; 44(Suppl 1): 22–29. doi:10.1111/j.1365-2184.2010.00726.x.

Pulse exposure of haematopoietic grafts to prostaglandin E₂ *in vitro* facilitates engraftment and recovery

L. M. Pelus, J. Hoggatt, and P. Singh

Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA

Abstract

Objectives: The aim of this study was to evaluate the effects of prostaglandin E₂ (PGE₂) on haematopoietic stem cell (HSC) function and determine its mechanism of action.

Materials and methods: HSC were exposed to PGE₂ for 2 h and effects on their homing, engraftment and self-renewal evaluated *in vivo*. Effects of PGE₂ on HSC cell cycle, CXCR4 expression and migration to SDF-1 α were analysed *in vitro*. Apoptosis was evaluated by examination of survivin expression and active caspase-3 levels.

Results: Equivalent haematopoietic reconstitution was demonstrated using 4-fold fewer PGE₂-treated cells compared to controls. Multilineage reconstitution was stable on secondary transplantation, indicating that PGE₂ affects long-term repopulating HSC (LT-HSC) and that enhanced chimaerism of PGE₂-pulsed cells results from their initial treatment. PGE₂ increased CXCR4 expression on mouse and human HSC, increased their migration to SDF-1 α *in vitro* and enhanced *in vivo* marrow homing 2-fold, which was blocked by a CXCR4 receptor antagonist. PGE₂ pulse exposure reduced apoptosis of mouse and human HSC, with increase in endogenous caspase inhibitor survivin, and concomitant decrease in active caspase-3. Two-fold more HSC entered the cell cycle and proliferated within 24 h after PGE₂ pulse exposure.

Conclusions: These studies demonstrate that short-term PGE₂ exposure enhances HSC function and supports the concept of utility of PGE₂ as an *ex vivo* strategy to improve function of haematopoietic grafts, particularly those where HSC numbers are limited.

Introduction

Prostaglandins (PGs) are extremely active short-lived lipids that act locally in a paracrine or autocrine fashion. There are no organs, tissues or cells in the body that are not affected by these bioactive lipids, either directly or through accessory mechanisms. All nucleated cells synthesize PGs by cleavage of the essential fatty acid, arachidonic acid from membrane phospholipids by phospholipase A₂, oxidation of free arachidonic acid by two cyclooxygenase enzymes (COX1 and COX2) and subsequent isomerization to an intermediate form, and synthesis of various mature PGs by specific synthases (2,3). A schematic outline of prostaglandin E₂ (PGE₂) biosynthesis is shown in Fig. 1. PGE₂ is the

predominant metabolite of arachidonic acid and is the most abundant eicosanoid (4,5). PGE₂ has been implicated in regulation of numerous physiological systems, and is the primary mediator of symptoms of fever (6) and inflammation (4,7), a regulator of atherosclerosis, blood pressure and strokes (7), and is involved in neoplastic transformation and cancer cell effects on host responses (4,8). Effects of PGE₂ are mediated through four highly conserved G-protein-coupled receptors (EP1–4) with overlapping as well as distinct signalling pathways (9,10) that can lead to seemingly opposing effects. EP receptor levels vary among tissues, and signalling pathways downstream of the same receptors can vary depending upon cell lineage.

Previously we have shown that PGE₂ regulates haematopoiesis, affecting both haematopoietic stem cell (HSC) and progenitor cell (HPC) functions. PGE₂ inhibits myelopoiesis *in vitro* and *in vivo* (11–13), and participates in a negative feedback loop regulating myeloid progenitor cell expansion (12,14,15). In contrast to its effects on myelopoiesis, PGE₂ promotes erythroid and multipotential colony formation *in vitro* (16,17). Early studies showed that short-term *ex vivo* treatment of bone marrow cells with PGE₂ could enhance progenitor cell proliferation (18,19); however, *in vivo* dosing led to little or no effect (20). We later showed that pulse exposure of mouse or human bone marrow cells to PGE₂ stimulated proliferation, cycling and differentiation of quiescent cells leading to an increase in cycling HPC, suggesting that PGE₂ enhances HSC function (21–23). These studies also clearly defined that dose, timing and length of exposure of haematopoietic cells to PGE₂ were critical factors defining stimulatory versus inhibitory effects on haematopoiesis. However, while these studies were the first to clearly implicate PGE₂ in positive regulation of haematopoiesis, stem cell function cannot be defined solely based on clonogenic assays. Elucidation of the effects of PGE₂ on HSC function requires demonstration that transplanted cells can repopulate haematopoiesis in myeloablated hosts (24). Recently, effects of PGE₂ on haematopoietic stem cell function have been revisited and studies in zebrafish and mice (25,26) validate the stimulatory effects of PGE₂ on HSC function that were suggested in earlier *in vitro* studies. In addition, we have defined mechanisms of action of PGE₂ on HSC function, particularly on HSC homing and self-renewal, which suggest that short-term exposure of haematopoietic grafts to PGE₂ can be utilized for therapeutic benefit in HSC transplantation (25). In this study, we describe pre-clinical findings supporting the therapeutic *ex vivo* utility of PGE₂ as a facilitator of HSC engraftment.

Materials and methods

Mouse and human cord blood

C57Bl/6 (CD45.2) mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). B6.SJL-PtcrA-Pep3B/BoyJ (BOYJ) (CD45.1), C57Bl/6 X BOYJ-F1 (CD45.1/CD45.2) and NOD.Cg-Prkdcscid IL2rgtm1Wjl/Sz (NSG) mice were bred in-house. Human umbilical cord blood (UCB) was obtained from Wishard Hospital, India-napolis, IN, with IRB approval.

Flow cytometry

For detection of SKL cells, streptavidin conjugated with PE-Cy7 [to stain for biotinylated MACS lineage antibodies (Miltenyi Biotech, Auburn, CA, USA)], c-kit-APC, Sca-1-PE or APC-Cy7, CD45.1-PE, CD45.2-FITC and CD34-PE were used (BD Biosciences, San Jose, CA, USA). For SLAM SKL, we used Sca-1-PE-Cy7, c-kit-FITC, CD150-APC (eBiosciences, San Diego, CA, USA), CD48-biotin (eBiosciences) and streptavidin-PE. UCB CD34⁺ cells were detected using anti-human-CD34-APC. For multi-lineage analysis, APC-Cy7-Mac-1, PE-Cy7-B-220 and APC-CD3 were used (BD Biosciences).

PGE₂ pulse exposure

Cells were incubated with 16,16-dimethyl prostaglandin E₂ (dmPGE₂) (Cayman Chemicals, Ann Arbor, MI, USA) (reconstituted in 100% ethanol) diluted in media, on ice, for 2 h. After incubation, cells were washed twice before use. Vehicle-treated cells were pulsed with equivalent concentration of ethanol.

Limiting dilution competitive and non-competitive transplantation

Whole bone marrow cells (CD45.2) were treated with 1 μM dmPGE₂ or 0.001% EtOH, washed, admixed with 2×10^5 congenic CD45.1 competitor marrow cells at various ratios, and transplanted into lethally irradiated CD45.1/CD45.2 mice. Peripheral blood CD45.1 and CD45.2 cells were determined monthly by FACS. HSC frequency was quantified by Poisson statistics using L-CALC software (Stem Cell Technologies, Vancouver BC, Canada). Competitive repopulating units (CRU) were calculated as described by Harrison (24). For secondary transplantation, 2×10^6 WBM from previously transplanted CD45.1/CD45.2 mice at 20 weeks post-transplant were injected into lethally irradiated CD45.1/CD45.2 mice in a non-competitive fashion.

HSPC homing

For competitive homing studies, SKL cells from CD45.2 and CD45.1 mice were FACS sorted, treated with dmPGE₂ or vehicle and 3×10^4 CD45.1 (vehicle or dmPGE₂ treated) plus 3×10^4 CD45.2 (dmPGE₂ or vehicle treated) SKL cells transplanted into lethally irradiated CD45.1/CD45.2 mice. Homed CD45.1 and CD45.2 SKL cells in bone marrow were determined after 16 h. To evaluate the role of CXCR4 in homing, Lin^{neg} CD45.2 cells were treated with vehicle or 1 μM dmPGE₂ plus 10 μM AMD3100 (AnorMed Inc., Vancouver, BC, Canada), and 2×10^6 treated cells injected into lethally irradiated CD45.1 mice and homed SKL cells analysed 16 h post-transplant. Homing of human CD34⁺ cells was evaluated in NSG mice. UCB mononuclear cells were pulsed with dmPGE₂ or vehicle and 4×10^7 cells transplanted into each of five sublethally irradiated (250 cGy) NSG mice. Homed CD34⁺ cells were analysed 16 h post-transplantation.

Analysis of CXCR4 expression and apoptosis

Mouse SKL cells or CD34⁺ UCB cells were pulsed with dmPGE₂ or vehicle, washed and cultured in RPMI-1640/10% HI-FBS at 37 °C for 24 h. CXCR4 expression was analysed using CXCR4-PE. Apoptotic levels were measured with FITC-annexin-V or FITC-anti-active caspase-3 after culture in RPMI-1640/2% HI-FBS at 37 °C for 24 h. For survivin and

active caspase-3 detection, cells were permeabilized and fixed using the CytoFix/CytoPerm kit (BD Biosciences) and stained with anti-active caspase-3-FITC Flow Kit (BD Biosciences) or survivin-PE (R&D Systems, Minneapolis, MN, USA).

Survivin and active caspase-3

Mouse SKL cells or CD34⁺ UCB cells were pulsed with dmPGE₂ or vehicle, washed and cultured in RPMI-1640/10% HI-FBS at 37 °C for 24 h. CXCR4, survivin and/or active caspase-3 were analysed by FACS.

Migration assays

Chemotaxis to SDF-1a *in vitro* was determined as described previously (27). Briefly, dmPGE₂- and vehicle-treated Lineage^{neg} bone marrow cells, UCB CD34⁺ cells or peripheral blood CD34⁺ cells mobilized by G-CSF were cultured in RPMI/10% HI-FBS overnight, washed, 2 × 10⁵ cells added to the top chamber of transwells, with or without rmSDF-1α (R&D Systems) in the bottom chamber, and incubated for 4 h at 37 °C. Cells migrating to the bottom chamber were enumerated by FACS. Per cent migration was calculated by dividing total cells migrated to lower well, by cell input, multiplied by 100.

Cell cycle analysis

Lineage^{neg} cells were treated with dmPGE₂ or vehicle and cultured with rmSCF (50 ng/ml) (R&D Systems), rhFlt-3 and rhTPO (100 ng/ml each) (Immunex, Seattle, WA, USA) for 20 h. Cells were stained for SLAM SKL, fixed, permeabilized and stained with Hoechst-33342 followed by Pyronin-Y. Proportion of SLAM SKL cells in G₀, G₁, S and G₂/M phase was determined by FACS.

Statistical analysis

All pooled values are expressed as mean ± SEM. Statistical differences were determined using paired or unpaired two-tailed *t*-test functions with Microsoft Excel as appropriate.

Results

PGE₂ increased long-term stem cell engraftment

Competitive repopulation transplantation models in mice allow for quantification of the ability of HSC to repopulate haematopoiesis. When congenic CD45.1 and CD45.2 mouse marrow cells were pulsed with vehicle or PGE₂ and transplanted in a limiting-dilution fashion, into CD45.1/CD45.2 hybrid mice, a model that permits head-to-head comparison of HSC populations; significantly enhanced HSC engraftment was observed for PGE₂ - pulsed bone marrow, compared to controls (Table 1). At 5 months post-transplantation, analysis of peripheral blood chimaerism showed significantly higher levels of white blood cells derived from PGE₂-treated marrow cells. Analysis of HSC frequency by Poisson statistics or by calculation of competitive repopulating units (CRU), indicated an ~4-fold increase in HSC frequency, strongly suggesting a direct effect on HSC. These results agree with similar studies performed in a conventional congenic transplant model (26). Myeloid cells, B and T lymphocytes were reconstituted with no obvious bias in lineage

reconstitution. To validate self-renewal capacity of *ex vivo* PGE₂-treated repopulating cells, marrow from primary transplantation recipients was harvested and transplanted into secondary recipients without any further *ex vivo* manipulation. Analysis of chimaerism at 24 weeks after secondary transplantation also showed significantly increased contribution to chimaerism from PGE₂-treated cells from primary recipients (Table 1). That enhanced chimaerism resulting from PGE₂ exposure in primary donors was maintained in secondary transplants without additional treatment, indicated that the effect of PGE₂ pulse exposure was stable and manifest in long-term repopulating stem cells (LT-HSC). On further serial transplantation, persistent enhanced chimaerism resulting from PGE₂ pulse exposure prior to transplantation into primary donors, was observed. Transplantation of human haematopoietic cells in immunodeficient mice offers a model system to evaluate human HSC function *in vivo* (28). In a similar fashion to that shown using mouse bone marrow cells, short-term *ex vivo* pulse exposure to PGE₂ enhanced engraftment of human UCB HSC in NOD/SCID-IL2- γ -receptor null (NSG) mice (Table 1).

PGE₂ increased HSC homing efficiency

Effects on cell division, homing or proliferation can positively or negatively affect HSC function. As we have previously shown that PGE₂ can have dual effects on haematopoiesis, we sought to define its mechanism of action to better understand the potential clinical utility of transient *ex vivo* PGE₂ exposure. Successful haematopoietic reconstitution requires that administered haematopoietic cells traffic/home to bone marrow niches where they can engraft, self-renew and differentiate. We therefore evaluated effects of PGE₂ exposure on these HSC functions.

To evaluate homing efficiency of HSC and determine whether the effect of PGE₂ pulse exposure results from direct PGE₂ effect, or is mediated through accessory cells, we FACS sorted congenic mouse Lineage^{neg} Sca-1⁺, c-kit⁺ (SKL) cells, enriched for LT-HSC, treated them *ex vivo* and directly compared homing efficiency of PGE₂-treated and vehicle-treated SKL cells head-to-head in CD45 hybrid mice. Pulse exposure of purified SKL cells to PGE₂ increased their homing efficiency 2-fold compared to controls (Fig. 2a). In traditional homing assays, increased homing of more differentiated Lineage^{neg}, c-kit⁺ HPC and Lineage^{neg} cells was not observed, suggesting that the enhanced homing effect of PGE₂ is specific to HSC.

The CXCR4 and SDF-1 α axis is a critical component of HSC marrow homing (29), and overexpression of CXCR4 in HSC enhances their *in vivo* homing and engraftment (30–32). To determine whether up-regulated CXCR4 would mediate PGE₂-enhanced HSC marrow homing, marrow cells were treated *ex vivo* with selective CXCR4 antagonist AMD3100 (33) after PGE₂ pulse exposure and prior to transplantation (Fig. 2b). As expected, PGE₂ pulse exposure increased SKL cell homing. Incubation of vehicle or PGE₂-pulsed cells with AMD3100 reduced SKL cell homing and abrogated PGE₂-improved homing efficiency. Reduction in HSC homing by AMD3100 is consistent with previous reports (34,35). To verify the enhancing effect of PGE₂ on human cells, CD34⁺ cells were isolated from cord blood, pulsed with PGE₂ or vehicle and their homing capacity analysed in NSG mice, a

validated model for human HSC homing (36). PGE₂ pulse exposure significantly enhanced homing efficiency of human UCB CD34⁺ cells in NSG mice (Fig. 2c).

PGE₂ increased HSC CXCR4 and migration to SDF-1 α

As PGE₂ enhancement of HSC homing was blocked by CXCR4 antagonism and PGE₂ has been reported to upregulate CXCR4 on CD34⁺ cells (37) and endothelial cells (38), and increase monocyte chemotaxis to SDF-1 α (39), we evaluated whether improved homing would result from HSC up-regulation of SDF-1 α /CXCR4 signalling and function. Pulse exposure to PGE₂ increased CXCR4 expression on mouse SKL cells and human UCB CD34⁺ cells (Table 2). HSC selectively migrate to SDF-1 α *in vitro* (40), a process that reflects their *in vivo* homing capacity. Vehicle- and PGE₂-treated mouse SKL cells and CD34⁺ cells from human UCB and G-CSF mobilized peripheral blood all demonstrated significant migration to 100 ng/ml SDF-1 α ; however, in all cases, chemotaxis of PGE₂-treated cells was significantly higher (Table 2), indicating that up-regulation of HSC CXCR4 coincided with enhanced migratory function. The enhancing effect of PGE₂ on chemotaxis to SDF-1 α was blocked by AMD3100, indicating that the observed effect was mediated through the CXCR4 receptor.

PGE₂ decreased apoptosis

Apoptosis is an important regulatory process in normal and malignant haematopoiesis and signalling downstream of PGE₂ receptors has been implicated in anti-apoptotic effects (41–43). This suggests that enhancement of HSC function by PGE₂ could result from enhanced HSC survival. Under reduced serum conditions, pulse exposure to PGE₂ reduced annexin-V and active caspase-3 in SKL cells, markers of apoptosis in mouse and human HSC (Fig. 3a,b). Furthermore, intracellular levels of the endogenous caspase-3 inhibitor survivin, were significantly higher in both SKL and CD34⁺ cells, consistent with our previous findings that survivin regulated apoptosis and proliferation in HSC (44,45), and studies by others that PGE₂ can increase survivin levels in cancer cells (46,47). QRT-PCR analysis of treated SKL cells and UCB CD34⁺ cells showed similarly elevated levels of survivin mRNA.

PGE₂ increased entry of HSC into the cell cycle

We have previously shown that survivin regulates entry of HSC into the cell cycle and their progression through it (44,45). Furthermore, β -catenin, which is implicated in HSC proliferation/self-renewal, lies downstream of EP receptor pathways (48). Ability of PGE₂ to modulate these cell cycle regulators suggests that increase in HSC self-renewal and proliferation might contribute to enhanced engraftment observed using PGE₂-pulsed cells. PGE₂ pulse exposure significantly increased the proportion of primitive LT-HSC, defined as SLAM (CD150⁺, CD48⁻) SKL cells, in the cell cycle (G₁ + S/G₂M) compared to controls (Fig. 4). No significant effect on rate of cell cycle completion by HPC or more differentiated cells, was observed (data not shown), strongly suggesting that effects of PGE₂ on cell cycle rate were selective.

Discussion

In vivo analysis of effects of short-term pulse exposure to PGE₂ clearly demonstrated that it has direct and stable effects on HSC function. Enhancement of HSC frequency and engraftment by PGE₂ treatment results from effects on HSC homing and cell cycle activity involving up-regulation of CXCR4 and survivin, with increased chemotactic response to SDF-1 α and reduced apoptosis. Ability to facilitate homing, survival and proliferation of HSC by short-term *ex vivo* PGE₂ exposure offers an exciting clinical translation strategy to improve haematopoietic transplantation, specially in transplant settings characterized by low HSC numbers, such as with umbilical cord blood cells and some mobilized peripheral blood stem cell products. Our experimental pre-clinical limiting dilution transplantation studies show that equivalent engraftment is achieved with 4-fold fewer PGE₂-treated cells compared to untreated cells. Homing and migration studies utilizing UCB CD34⁺ cells also clearly support potential translation of short-term PGE₂ exposure to human haematopoietic grafts.

While *ex vivo* utility of PGE₂ is clear, it will be interesting to determine whether enhanced HSC engraftment/recovery could also be achieved by administering PGE₂ *in vivo* or if PGE₂ used *in vivo* could further facilitate engraftment of HSC exposed to PGE₂ *ex vivo*. In COX2 knockout mice, haematopoietic recovery from chemotherapy is delayed (49) suggesting that PGE₂ production is critical for HSC expansion. However, it must be kept in mind that while short-term exposure to PGE₂ can enhance HSC function, prolonged administration inhibits myelopoiesis (11,50), which is supported by inhibition of prostaglandin biosynthesis *in vivo* leading to expansion of myelopoiesis (51), at least in mice. Nevertheless, combination of transient *ex vivo* PGE₂ exposure with selective modulation of *in vivo* PGE₂ biosynthesis may result in significant further improvements in HSC function.

Acknowledgements

This study was supported by NIH grants HL069669, HL079654 and HL096305 (to LMP). JH is supported by training grant DK07519. Flow cytometry was performed in the Flow Cytometry Resource Facility of the Indiana University Simon Cancer Center (NCI P30 CA082709).

References

1. Miller SB (2006) Prostaglandins in health and disease: an overview. *Semin. Arthritis Rheum* 36, 37–49. [PubMed: 16887467]
2. Murakami M, Kudo I (2004) Recent advances in molecular biology and physiology of the prostaglandin E₂-biosynthetic pathway. *Prog. Lipid Res* 43, 3–35. [PubMed: 14636669]
3. Park JY, Pillinger MH, Abramson SB (2006) Prostaglandin E₂ synthesis and secretion: the role of PGE₂ synthases. *Clin. Immunol* 119, 229–240. [PubMed: 16540375]
4. Murakami M, Kudo I (2006) Prostaglandin E synthase: a novel drug target for inflammation and cancer. *Curr. Pharm. Des* 12, 943–954. [PubMed: 16533161]
5. Serhan CN, Levy B (2003) Novel pathways and endogenous mediators in anti-inflammation and resolution. *Chem. Immunol. Allergy* 83, 115–145. [PubMed: 12947982]
6. Lazarus M (2006) The differential role of prostaglandin E₂ receptors EP3 and EP4 in regulation of fever. *Mol. Nutr. Food Res* 50, 451–455. [PubMed: 16534751]
7. Samuelsson B, Morgenstern R, Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. *Pharmacol. Rev* 59, 207–224. [PubMed: 17878511]

8. Hull MA, Ko SC, Hawcroft G (2004) Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? *Mol. Cancer Ther* 3, 1031–1039. [PubMed: 15299086]
9. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes and signaling. *Annu. Rev. Pharmacol. Toxicol* 41, 661–690. [PubMed: 11264472]
10. Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. *J. Biol. Chem* 282, 11613–11617. [PubMed: 17329241]
11. Gentile P, Byer D, Pelus LM (1983) In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2. *Blood* 62, 1100–1107. [PubMed: 6578856]
12. Pelus LM, Broxmeyer HE, Kurland JI, Moore MA (1979) Regulation of macrophage and granulocyte proliferation. Specificities of prostaglandin E and lactoferrin. *J. Exp. Med* 150, 277–292. [PubMed: 313430]
13. Pelus LM, Broxmeyer HE, Moore MA (1981) Regulation of human myelopoiesis by prostaglandin E and lactoferrin. *Cell Tissue Kinet* 14, 515–526. [PubMed: 7273093]
14. Kurland JI, Broxmeyer HE, Pelus LM, Bockman RS, Moore MA (1978) Role for monocyte-macrophage-derived colony-stimulating factor and prostaglandin E in the positive and negative feedback control of myeloid stem cell proliferation. *Blood* 52, 388–407. [PubMed: 307418]
15. Kurland JI, Pelus LM, Ralph P, Bockman RS, Moore MA (1979) Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor cell proliferation. *Proc. Natl. Acad. Sci. USA* 76, 2326–2330. [PubMed: 313054]
16. Lu L, Pelus LM, Broxmeyer HE (1984) Modulation of the expression of HLA-DR (Ia) antigens and the proliferation of human erythroid (BFU-E) and multipotential (CFU-GEMM) progenitor cells by prostaglandin E. *Exp. Hematol* 12, 741–748. [PubMed: 6436046]
17. Lu L, Pelus LM, Piacibello W, Moore MA, Hu W, Broxmeyer HE (1987) Prostaglandin E acts at two levels to enhance colony formation in vitro by erythroid (BFU-E) progenitor cells. *Exp. Hematol* 15, 765–771. [PubMed: 3497050]
18. Feher I, Gidali J (1974) Prostaglandin E2 as stimulator of haemopoietic stem cell proliferation. *Nature* 247, 550–551. [PubMed: 4150455]
19. Verma DS, Spitzer G, Zander AR, McCredie KB, Dicke KA (1981) Prostaglandin E1-mediated augmentation of human granulocyte-macrophage progenitor cell growth in vitro. *Leuk. Res* 5, 65–71. [PubMed: 7230872]
20. Gidali J, Feher I (1977) The effect of E type prostaglandins on the proliferation of haemopoietic stem cells in vivo. *Cell Tissue Kinet* 10, 365–373. [PubMed: 884706]
21. Pelus LM (1982) Association between colony forming units-granulocyte macrophage expression of Ia-like (HLA-DR) antigen and control of granulocyte and macrophage production. A new role for prostaglandin E. *J. Clin. Invest* 70, 568–578. [PubMed: 6286727]
22. Pelus LM (1982) CFU-GM expression of Ia-like, HLA-DR, antigen: an association with the humoral control of human granulocyte and macrophage production. *Exp. Hematol* 10, 219–231.
23. Pelus LM (1989) Modulation of myelopoiesis by prostaglandin E2: demonstration of a novel mechanism of action in vivo. *Immunol. Res* 8, 176–184. [PubMed: 2664032]
24. Harrison DE (1980) Competitive repopulation: a new assay for long-term stem cell functional capacity. *Blood* 55, 77–81. [PubMed: 6985804]
25. Hoggatt J, Singh P, Sampath J, Pelus LM (2009) Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. *Blood* 113, 5444–5455. [PubMed: 19324903]
26. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM et al. (2007) Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. *Nature* 447, 1007–1011. [PubMed: 17581586]
27. Fukuda S, Pelus LM (2006) Internal tandem duplication of Flt3 modulates chemotaxis and survival of hematopoietic cells by SDF1alpha but negatively regulates marrow homing in vivo. *Exp. Hematol* 34, 1041–1051. [PubMed: 16863910]
28. Dick JE, Bhatia M, Gan O, Kapp U, Wang JC (1997) Assay of human stem cells by repopulation of NOD/SCID mice. *Stem Cells* 15(Suppl. 1), 199–203. [PubMed: 9368342]

29. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T et al. (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science* 283, 845–848. [PubMed: 9933168]
30. Brenner S, Whiting-Theobald N, Kawai T, Linton GF, Rudikoff AG, Choi U et al. (2004) CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. *Stem Cells* 22, 1128–1133. [PubMed: 15579633]
31. Kahn J, Byk T, Jansson-Sjostrand L, Petit I, Shivtiel S, Nagler A et al. (2004) Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. *Blood* 103, 2942–2949. [PubMed: 15070669]
32. Kollet O, Spiegel A, Peled A, Petit I, Byk T, Hershkovitz R et al. (2001) Rapid and efficient homing of human CD34(+)/CD38(-/low)/CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. *Blood* 97, 3283–3291. [PubMed: 11342460]
33. Hatse S, Princen K, Bridger G, De CE, Schols D (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. *FEBS Lett* 527, 255–262. [PubMed: 12220670]
34. Christopherson KW, Hangoc G, Mantel CR, Broxmeyer HE (2004) Modulation of hematopoietic stem cell homing and engraftment by CD26. *Science* 305, 1000–1003. [PubMed: 15310902]
35. Fukuda S, Bian H, King AG, Pelus LM (2007) The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. *Blood* 110, 860–869. [PubMed: 17416737]
36. Jetmore A, Plett PA, Tong X, Wolber FM, Breese R, Abonour R et al. (2002) Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients. *Blood* 99, 1585–1593. [PubMed: 11861272]
37. Goichberg P, Kalinkovich A, Borodovsky N, Tesio M, Petit I, Nagler A et al. (2006) cAMP-induced PKCzeta activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors. *Blood* 107, 870–879. [PubMed: 16204315]
38. Salcedo R, Zhang X, Young HA, Michael N, Wasserman K, Ma WH et al. (2003) Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. *Blood* 102, 1966–1977. [PubMed: 12791666]
39. Panzer U, Ugucconi M (2004) Prostaglandin E2 modulates the functional responsiveness of human monocytes to chemokines. *Eur. J. Immunol* 34, 3682–3689. [PubMed: 15484190]
40. Kim CH, Broxmeyer HE (1998) In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. *Blood* 91, 100–110. [PubMed: 9414273]
41. Fernandez-Martinez A, Molla B, Mayoral R, Bosca L, Casado M, Martin-Sanz P (2006) Cyclooxygenase 2 expression impairs serum-withdrawal-induced apoptosis in liver cells. *Biochem. J* 398, 371–380. [PubMed: 16800815]
42. George RJ, Sturmoski MA, Anant S, Houchen CW (2007) EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. *Prostaglandins Other Lipid Mediat* 83, 112–120. [PubMed: 17259077]
43. Negrotto S, Pacienza N, D'Atri LP, Pozner RG, Malaver E, Torres O et al. (2006) Activation of cyclic AMP pathway prevents CD34(+) cell apoptosis. *Exp. Hematol* 34, 1420–1428. [PubMed: 16982335]
44. Fukuda S, Pelus LM (2001) Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. *Blood* 98, 2091–2100. [PubMed: 11567995]
45. Fukuda S, Foster RG, Porter SB, Pelus LM (2002) The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. *Blood* 100, 2463–2471. [PubMed: 12239157]
46. Baratelli F, Krysan K, Heuze-Vourc'h N, Zhu L, Escudero B, Sharma S et al. (2005) PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. *J. Leukoc. Biol* 78, 555–564. [PubMed: 15908458]

47. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y et al. (2004) COX-2-dependent stabilization of survivin in non-small cell lung cancer. *FASEB J* 18, 206–208. [PubMed: 14597555]
48. Regan JW (2003) EP2 and EP4 prostanoid receptor signaling. *Life Sci* 74, 143–153. [PubMed: 14607241]
49. Lorenz M, Slaughter HS, Wescott DM, Carter SI, Schnyder B, Dinchuk JE et al. (1999) Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. *Exp. Hematol* 27, 1494–1502. [PubMed: 10517490]
50. Pelus LM, Gentile PS (1988) In vivo modulation of myelopoiesis by prostaglandin E2. III. Induction of suppressor cells in marrow and spleen capable of mediating inhibition of CFU-GM proliferation. *Blood* 71, 1633–1640. [PubMed: 3163505]
51. Pelus LM (1989) Blockade of prostaglandin biosynthesis in intact mice dramatically augments the expansion of committed myeloid progenitor cells (colony-forming units-granulocyte, macrophage) after acute administration of recombinant human IL-1 alpha. *J. Immunol* 143, 4171–4179. [PubMed: 2592770]




Figure 1. Outline of prostaglandin E₂ (PGE₂) biosynthesis from membrane phospholipids. COX, cyclooxygenase; PLA₂, phospholipase A₂.




Figure 2. PGE₂ pulse exposure enhances homing of mouse and human HSC.

(a) SKL cells were isolated from congenic mice by FACS sorting and treated with vehicle or 1 μ M 16, 16-dimethyl PGE₂ (dmPGE₂) on ice for 2 h. After incubation, cells were washed and 3×10^4 vehicle-or dmPGE₂-treated CD45.1 and 3×10^4 vehicle-or dmPGE₂-treated CD45.2 cells injected into lethally irradiated CD45.1/CD45.2 hybrid mice. Number of homed CD45.1 and CD45.2 SKL cells was quantified in bone marrow at 16 h post-transplantation. Data (mean \pm SEM) from 10 mice with treatment groups of five mice, switched to rule out bias. (b) Bone marrow cells from CD45.2 mice were treated with vehicle or dmPGE₂, washed, incubated in the presence or absence of 10 μ M AMD3100 for 30 min and transplanted into lethally irradiated CD45.1 mice. Number of homed CD45.2 SKL cells was quantified in bone marrow at 16 h post-transplantation. Data (mean \pm SEM) from three mice per group each assayed individually. (c) Umbilical cord blood mononuclear cells were isolated, treated with vehicle or dmPGE₂ and injected into sublethally irradiated NSG mice. Bone marrow was analysed after 16 h for number of homed human CD45⁺, CD34⁺ cells. Data (mean \pm SEM) from five mice per group each assayed individually.




Figure 3. PGE₂ decreases apoptosis and increases level of intracellular survivin.

(a) Lineage-depleted mouse bone marrow cells were treated with dmPGE₂ or vehicle for 2 h, washed and cultured in 2% HI-FBS without growth factors for 24 h at 37 °C. After culture, cells were stained for SKL. Apoptosis was measured with FITC-annexin-V (left panel). Replicate cells were permeabilized and stained with anti-active caspase-3-FITC (middle panel) or anti-survivin-PE (right panel). Data expressed as fold-change induced by dmPGE₂ pulse exposure compared to vehicle-treated cells. (b) Fold-change in active caspase-3 (left panel) and intracellular survivin (right panel) in permeabilized PGE₂-treated UCB CD34⁺

cells relative to vehicle-treated cells after culture in 2% HI-FBS without growth factors for 24 h at 37 °C.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. PGE₂ increases cell cycle of SLAM SKL cells.

Lineage-depleted mouse bone marrow cells were treated with dmPGE₂ or vehicle for 2 h, washed and cultured with 50 ng/ml rmSCF and 100 ng/ml each of rhFlt3 and rhTpo for 20 h. Cells were stained for SLAM (CD150⁺, CD48⁻) SKL, Hoechst-33342 and pyronin-Y and proportion of SLAM SKL cells in G₀, G₁, S and G₂/M phases of the cell cycle determined by flow cytometry. Data (mean ± SEM) from nine mice each assayed individually. **P* < 0.05.

Table 1.Transient exposure of haematopoietic cells to PGE₂ enhances HSC engraftment

Group	Time of exposure (h) ^a	Fold increase HSC frequency ^b	Fold increase CRU ^c	% PB chimaerism congenic mice ^d		% PB chimaerism NSG ^e
				Primary	Secondary	
Vehicle	2	–	–	13.3 ± 1.4	5.1 ± 0.13	2.3
1 μM dmPGE ₂	2	4.12	3.4	40.7 ± 5.0*	34.2 ± 0.51*	11.0

^aWhole mouse bone marrow cells or human umbilical cord blood mononuclear cells were treated on ice with 0.001% ethanol or 1 μM dmPGE₂ for 2 h and washed twice in ice-cold PBS before transplant.

^bHSC cell frequency was calculated by Poisson statistics at 20 weeks post-transplant (P0 vehicle = 89 586; P0 PGE₂ = 21 753) using L-CALC software (Stem Cell Technologies, Vancouver, BC, Canada).

^cCRU were calculated based on PB chimaerism at 20 weeks in primary transplants according to the method of Harrison (24).

^dChimaerism in PB is shown at 20 weeks in primary transplant and 24 weeks in secondary transplant (mean ± SEM). Data are for 10 mice in two experiments, each assayed individually.

^eChimaerism in PB of NSG (*NOD.Cg-Prkdcscid IL2rgtm1 Wjl/ Sz*) mice at 8 weeks post-transplant with vehicle-or PGE₂-pulsed umbilical cord blood mononuclear cells.

* $P < 0.05$.

Table 2.PGE₂ enhances mouse and human HSC CXCR4 expression and migration to SDF-1 α

	<u>SKL cells</u>		<u>UCB CD34⁺ cells^a</u>		<u>MPB CD34⁺ cells^a</u>	
	Vehicle	dmPGE ₂ ^b	Vehicle	dmPGE ₂ ^b	Vehicle	dmPGE ₂ ^b
% increase CXCR4 ^c	6.99 ± 2.5	26.82 ± 4.4 *	6.88	17.31	–	–
% migration to SDF-1 ^d	46.8 ± 4.8	67.1 ± 5.7 *	27.7 ± 1.2	55.6 ± 3.3 *	23.2 ± 1.1	41.4 ± 1.8 *

^aCD34⁺ cells were isolated from umbilical cord blood or apheresis products of normal donors mobilized with G-CSF for allogeneic transplantation.

^bMouse SKL cells or human CD34⁺ cells were treated on ice with 0.001% ethanol or 1 μ M dmPGE₂ for 2 h, washed, and resuspended in media with 10% HI-FCS and cultured at 37 °C for 16 h.

^cCells were pulsed with dmPGE₂ and cultured as described above. CXCR4 expression was analysed by flow cytometry. Data are expressed as percent-age change in mean fluorescence intensity of CXCR4 expression resulting from treatment with vehicle or dmPGE₂.

^dCells were pulsed with dmPGE₂ and cultured as described above. After incubation, cells were washed, resuspended in RPMI/0.5% BSA and allowed to migrate to 100 ng/ml recombinant mouse or human SDF-1 α for 4 h. Total cell migration was quantified by flow cytometry. Data (mean \pm SEM) are from three experiments.

* $P < 0.05$.